Regeneron Pharmaceuticals (REGN) Income from Continuing Operations (2009 - 2026)

Regeneron Pharmaceuticals' Income from Continuing Operations history runs 18 years deep, the most recent figure standing at 727200000.0 for Q1 2026.

• On a quarterly basis, Income from Continuing Operations fell 10.08% year-over-year to 727200000.0 in Q1 2026; TTM through Mar 2026 was 4423400000.0, a 1.69% decrease from a year earlier, with the FY2025 full-year figure at 4504900000.0, up 2.09% from the prior year.
• Income from Continuing Operations declined to 727200000.0 in Q1 2026 per REGN's latest filing, from 844600000.0 in the prior quarter.
• Across five years, Income from Continuing Operations topped out at 1460000000.0 in Q3 2025 and bottomed at 722000000.0 in Q1 2024.
• The 5-year median for Income from Continuing Operations is 973500000.0 (2022), against an average of 1055100000.0.
• Across the five-year window, Income from Continuing Operations slumped 72.5% in 2022 and surged 47.9% in 2024, its largest moves.
• Year by year, Income from Continuing Operations stood at 1197100000.0 in 2022, then retreated by 3.13% to 1159600000.0 in 2023, then decreased by 20.86% to 917700000.0 in 2024, then dropped by 7.97% to 844600000.0 in 2025, then retreated by 13.9% to 727200000.0 in 2026.
• Per Business Quant, the three latest REGN Income from Continuing Operations figures stand at 727200000.0 (Q1 2026), 844600000.0 (Q4 2025), and 1460000000.0 (Q3 2025).